Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients who received semaglutide tablets than placebo: semaglutide tablets 14 mg once daily (41%), semaglutide tablets 7 mg once daily (32%) and placebo (21%), including severe reactions (semaglutide tablets 14 mg 2.0%, semaglutide tablets 7 mg 0.6%, placebo 0.3%)
As always, any changes made to a medication regimen, including dosage adjustments, should be discussed and managed by a healthcare provider
Women with polycystic ovary syndrome, a condition characterized by insulin resistance, may see improvements in metabolic parameters, though semaglutide is not specifically approved for PCOS treatment
[31] In February 2018, authorization was granted in the European Union, [16] [84] in March 2018 in Japan, [32] and in August 2019 in Australia
These precautions protect both your health and financial investment in these medications
-1775582746855.png&w=384&q=75)
